Jeno Gyuris, PhD: Executive Vice President, Research & Development – Chief Scientific Officer. Dr. Gyuris brings over 20 years of biopharma experience and deep understanding of basic cancer and translational biology as well as oncology drug discovery and development to Quiet Therapeutics. He most recently served as the Chief Scientific Officer of AVEO Oncology where he oversaw all research activities. Prior to joining AVEO he was Vice President of Molecular Technologies at GPC Biotech AG, formerly Mitotix Inc. Dr. Gyuris has received his Ph.D. in Molecular Biology from the University of Szeged and was a postdoctoral fellow at Massachusetts General Hospital/Harvard Medical School.
David Altreuter, PhD: VP CMC. Since 2001 Dr. Altreuter has been engaged in the design, development, and production of highly-engineered injectable particle drugs. He previously held Director-level positions leading Formulation and project teams at Selecta Biosciences, Manufacturing at Alnylam Pharmaceuticals and also performing Formulation and Process Development at Acusphere. Dr. Altreuter received his B.S.E in Chemical Engineering from Princeton University and Ph.D. in Chemical Engineering from the University of California, Berkeley.
Evgenia Alpert, MD, PhD: Head of Research. Joined Quiet from Quark Pharmaceuticals where she held the position of Project Director and Director of siRNA Pharmacology. While at Quark she was involved in the development of several projects including the development of novel non-invasive siRNA delivery systems. Dr. Alpert received her MD degree and is trained as a pediatric surgeon. She received her PhD from the Dept. of Pharmacology, Hebrew University of Jerusalem and was a post-doctoral fellow at the Department of Physiology, University of California San Francisco.